Biophytis S.A. (ALBPS.PA) Stock

About Biophytis S.A.

Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.

Biophytis S.A. is led by CEO Stanislas Veillet, employs 20 people, headquartered in Paris, FR, publicly traded since 2015.

over the past 52 weeks the stock has ranged between $0.00 and $0.21, and currently trades 61.9% below its 52-week high.

Official website: www.biophytis.com